Evidence map›Paper›PMID 41497399›Full record

ArticleiScience2025

Maximizing survival benefit with precision therapy based on progressive patterns after immunochemotherapy in metastatic esophageal cancer.

Yingnan Liu, Shuping Cheng, Taotao Dong, Butuo Li, Chao Jiang, Jinming Yu, Linlin Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yingnan LiuShandong University Cancer Center, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250117, China.
Shuping ChengDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jiyan Road 440, Jinan 250117, China.
Taotao DongDepartment of Obstetrics and Gynecology, Qilu Hospital of Shandong University, 107 West Wenhua Road, Jinan, Shandong 250063, China.
Butuo LiDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jiyan Road 440, Jinan 250117, China.
Chao JiangDepartment of Otorhinolaryngology Head and Neck Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250021, China.
Jinming YuShandong University Cancer Center, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250117, China.
Linlin WangShandong University Cancer Center, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250117, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to define optimal treatment strategies for metastatic esophageal cancer with different progressive patterns after first-line immunotherapy (IO) resistance. Patients were stratified into oligoprogression and polyprogression, with further subclassifications (repeat oligoprogression [REO]/induced oligoprogression [INO]/de-novo polyprogression [DNP]/repeat polyprogression [REP]). Oligoprogression patients receiving radiotherapy (RT) had longer progression-free survival (PFS) (9.4 vs. 5.8 months,

Indexed as

OncologyTherapeutics

Identifiers

PMID41497399
PMCPMC12767177

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.